Clovis Oncology (CLVS) Stock: The Low Down On Approval

Clovis Oncology (NASDAQ:CLVS) On Monday, Clovis Oncology stock closed higher by 9% after it announced that the FDA had approved its drug. The drug in question is known as rucaparib – to be marketed as Rubraca. This was for early approval of rucaparib, which is used to treat patients with advanced ovarian cancer. The stock … Read more